ReviewFrontiers in cardiovascular medicine2025
The role of VAP-1 in cardiovascular disease: a review.
Review in Frontiers in cardiovascular medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Novel glycine amides, semicarbazides and fluoroallylamines as inhibitors of the amine oxidase vascular adhesion protein-1 (VAP-1).RSC medicinal chemistry · 2026Article
- Triglyceride-glucose index and atherogenic index of plasma as predictors of cardiovascular risk in rectal cancer survivors.Frontiers in cardiovascular medicine · 2026Article
- Hydralazine Attenuates Lipopolysaccharide-Induced Murine Myocardial Dysfunction by Inhibition of Semicarbazide-Sensitive Amine Oxidase.Antioxidants (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiovascular diseases (CVD) remain the primary cause of morbidity and mortality in developed countries, highlighting the urgent need to identify biomarkers associated with CVD and its risk factors. Vascular adhesion protein-1 (VAP-1), a 170 kDa surface molecule expressed predominantly by endothelial cells, smooth muscle cells, and adipocytes, has garnered significant attention in this field. Beyond its role in inducing inflammatory mediators, VAP-1 is closely linked to coronary artery disease, heart failure, diabetes, obesity, and other CVDs, along with their associated risk factors. Notably, elevated plasma VAP-1 activity has been observed in patients with CVD and diabetes. The toxic metabolites produced by its enzymatic activity contribute to vascular endothelial injury and oxidative stress, thereby accelerating atherosclerosis and diabetes-related cardiovascular complications. Consequently, understanding the pathophysiological roles of VAP-1 in CVD has become a major research focus. This review examines the effects of VAP-1 on CVD pathogenesis and explores the therapeutic potential of VAP-1 inhibitors in managing these conditions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.